Polypeptide With Localisation/Targeting Motif TRIZ Cases

An Amyelois piggyBac-like transposase boosts excision and transposition while reducing host inactivation for stable heterologous DNA expression.

A multi-antigen nucleic acid vaccine targets WNT-pathway neoantigens to boost CD8+ T cell response and improve checkpoint-resistant cancer treatment.

Engineered T-cell receptors bind mutant RAS peptides on HLA-C*08:02 to trigger selective tumor cell killing when inhibitors fall short.

Novel CARs using DAP10 or DAP12 with SAP or EAT2 help NK cells overcome inhibitory signaling and improve solid tumor killing with better safety.

By fusing PiggyBac catalytic activity with MosI DNA binding, this case enables precise TTAA integration with shorter ITRs and fewer transposase molecules.

A split deaminase composition enables A-to-G and C-to-T editing in plant organelle DNA, overcoming guide RNA delivery limits.

Mutant IL-2 linked to a PD-1 antibody shifts activation toward cytotoxic T cells, reducing Treg-driven immunosuppression and toxicity.

A small molecule disrupts receptor-signaling heterodimerization, giving CAR cells reversible potency control to limit toxic effects.

A dynamin 1-derived peptide blocks tau-driven microtubule over-assembly, preserves vesicle endocytosis, and restores synaptic transmission.

Engineered CAR-Treg cells bind citrullinated proteins in HS lesions to improve local immune control without broad corticosteroid suppression.

A chimeric RSV F linked to PIV3 membrane domains improves viral incorporation and induces stronger neutralizing immunity in recombinant vaccine vectors.

A CD3/TCR agonist with IL-7 and IL-21 replaces CD28 stimulation to shorten CAR-T preparation to 1-4 days while reducing cost and differentiation.

Dual CD19/CD20 recognition helps CAR-T cells overcome antigen escape and improve tumor killing in relapsed B-cell treatment.

A modular receptor links target-cell binding with engulfment signaling to boost phagocytosis and inflammatory clearance of diseased cells.

High-specificity DLL3 antibodies enable CAR-T and CAR-NK targeting of neuroendocrine tumors while limiting cross-reactivity and side effects.

A short RRRRSNRRG peptide improves cell membrane permeability and boosts transfer of nucleic acids, polypeptides, and drugs into eukaryotic cells.

Targeted IL-18 mutations reduce IL-18BP binding while preserving receptor signaling, improving immune activation and anti-tumor activity.

Directly glycosylated arginine-rich peptides improve blood-brain barrier delivery of therapeutic SSOs while lowering dose and toxicity.

Modular FAP-binding chimeric proteins reprogram CAFs, enhance antigen presentation, and localize therapy within tumors.

Split Cas9 cleavage and FokI dimerization reduce off-target DNA cutting while enabling precise genome editing and recombination.

Chimeric cell-permeant polypeptides restore endothelial function by reducing p38 MAPK phosphorylation and improving vascular relaxation.

Antibodies targeting the MUC1* PSMGFR region improve solid tumor cell killing while reducing off-tumor toxicity in CAR, BiTE, and ADC use.

CRISPR suppression of autophagy genes in CAR-T lymphocytes improves persistence and anti-tumor activity in glucose-competitive solid tumors.

Modified Conus-derived peptides selectively inhibit extrasynaptic GluN2B receptors to reduce neuronal apoptosis while preserving synaptic function.

Synthetic MVA DNA fragments replace restricted vector stocks while preserving strong coronavirus antigen expression and long-term immunity.

A novel TISEVO translation initiation sequence boosts mammalian recombinant protein yield while preserving protein quality and expression predictability.

Dual CD19/CD20 binding motifs help engineered T cells overcome tumor evasion and improve lymphoma and leukemia cell killing.

Engineered CAR immune cells use interchangeable receptor domains to expand tumor antigen targeting while preserving signaling and cancer cell killing.

Engineered CAR-T cells that bind CD20 and BCMA improve B cell depletion and support longer remission in autoimmune disease and cancer.

Engineered anti-DLL3 CAR-T receptors use scFv or sdAb binding and co-stimulatory signaling to selectively destroy DLL3-expressing SCLC cells.

Fusosomes use fusogen-equipped lipid bilayers to deliver membrane proteins to target cells with higher specificity while avoiding viral genetic contamination.

Muscle-specific promoters and regulatory elements focus nuclease expression in skeletal and cardiac tissue to restore dystrophin in DMD.

Guide RNA-directed fusion proteins add or remove RNA methyl groups with limited off-target editing, enabling precise epigenetic control.

Monoclonal anti-Aβ antibodies use optimized variable regions to bind toxic soluble and fibrillar Aβ, improving plaque clearance and neutralization.

Novel Cas protein variants expand PAM recognition and improve eukaryotic expression, enabling more precise and adaptable gene editing.

Small complementary luciferase polypeptides detect intermolecular interactions with high sensitivity while minimizing steric hindrance and expression issues.

Pooling enriched CD4+ and CD8+ T cells at an optimized ratio in serum-free media improves transduction success, viability, and expansion.

Using Nme2Cas9 fused to a deaminase expands PAM-compatible editing sites and improves single-base precision with fewer off-target effects.

Engineered EGFRvIII binders improve solid-tumor immune targeting while minimizing wild-type EGFR binding and off-tumor toxicity.

Short teleost invariant chain MPD fragments boost T-cell responses to multiple cancer antigens while fitting vector size limits.

Engineered CAR T-cells target CAIX and CD70 while locally secreting checkpoint antibodies to improve solid tumor killing and limit off-tumor effects.

A mutant AID editor cuts molecular weight while boosting targeted single-base mutation efficiency and reducing off-target DNA editing.

Base editing inactivates endogenous CD2 to prevent CAR immune cell fratricide while preserving genomic stability and anti-neoplasia activity.

Engineered block copolymer silk proteins enable scalable microbial production of strong, flexible fibers in microfiber diameters.

Guide RNAs with dCas9 fusion proteins target HBG1/HBG2 and BCL11A to raise fetal hemoglobin with improved safety for hemoglobinopathies.

Engineered hPSC-derived NK cells use ID2, NFIL3, SPI1 and CAR knock-ins to improve tumor killing, persistence, and reproducible production.

CLL-1-directed CAR-T cells deplete pathogenic macrophages in MS, targeting smoldering neuroinflammation beyond T- and B-cell therapies.

Cas8-FokI fusion proteins and modified guides simplify Type I Cascade expression in eukaryotic cells while improving DNA targeting and cleavage.

CARs tuned to β2M-associated and β2M-free HLA-G isoforms help eliminate immunosuppressive tumor cells and improve solid tumor targeting.

Surface-displayed yeast enzymes with in-situ UDPG regeneration cut rebaudioside synthesis cost while improving reuse and conversion.

This case uses epithelial-specific CAR-Tregs to target inflamed tissues and address inadequate GVHD treatment.

This case uses a self-cleavage-free IgA protease and Fc fusion to target IgA deposition with longer therapeutic action.

Engineered TCRs target glioblastoma antigens despite a suppressive tumor microenvironment.

This case resolves poor eukaryotic CRISPR-Cas3 editing with pre-crRNA and bipartite nuclear localization for large DNA deletions.

To address limited MUC18 antagonists, this case develops high-affinity antibodies for ADCs, CARs, targeted therapy, and diagnosis.

This case uses c-Jun overexpression with Regnase-1 or PTPN2 reduction to limit T cell exhaustion and preserve cytotoxicity.

Targeting CD20 while engaging Dectin-1 promotes localized phagocytosis, cytokine signaling, and adaptive immune stimulation.

A liver-specific promoter drives codon-optimized GAA expression to sustain therapy while reducing infusion frequency and antibody formation.

Engineered CAR immune cells recognize HLA-G on cancer cells, extending targeted cytotoxicity to cancers resistant to conventional treatment.

A capped-sgRNA complex recruits translational machinery to specific RNA targets.

A fusion peptide combines a TLR-binding domain with a cell-penetrating sequence to block immune signaling pathways.

Chimeric receptors in engineered immune cells modulate the tumor microenvironment to enhance therapeutic efficacy.

Plant-expressed RBD-Fc fusion protein induces immune response without His-tag side effects or ultra-low temperature storage.

Co-expressing CX3CR1 and IL-15 in CAR-T cells overcomes suppressive microenvironments, enabling effective solid tumor infiltration.

CRT-2 and CRT-3 antibodies target CLEC14A-expressing cells, resolving the trade-off between specific targeting and systemic toxicity in cancer treatment.

Light-activated anion channel proteins modulate membrane potentials by allowing multiple ions to pass through the cell membrane in response to light.

Sulfated polypeptides enhance systemic delivery to muscle tissues while reducing accumulation in non-target organs like the liver and kidneys.

Fully human CAR T cells target folate receptor alpha to eliminate tumor burden while avoiding human anti-mouse antibody production.

A dual-activating costimulatory receptor modifies T cells to produce strong clustering effects and specific tumor cell killing.

Unconjugated monoclonal antibodies inhibit the Nectin4-TIGIT interaction, restoring anti-cancer immunity without adding treatment complexity.

High-affinity BCMA-CAR-T cells eliminate relapsed multiple myeloma tumors through targeted cytotoxic activity.

Peptide inhibitors prevent FUS transportin binding to stop nuclear translocation and treat glomerulosclerosis.

Humanizing CAR scFv frameworks stabilizes binding domains, preventing self-aggregation that causes T cell exhaustion.

A covalently linked RGEN protein and cell-penetrating peptide complex traverses the bacterial membrane to enter the cell.

Directing oxygen-sensitive nitrogenase components via mitochondrial targeting peptides enables aerobic expression and purification of active enzyme complexes.

Antibodies bind specific toxic Aβ oligomer conformations to reduce plaque accumulation and neurodegeneration in Alzheimer's disease.

Engineered meganucleases cleave the HAO1 gene to reduce oxalate production, addressing primary hyperoxaluria type 1.

Replacing endogenous TIGIT with human sequences creates a relevant biological context that reduces clinical trial failure rates during antibody development.

Fc fusion proteins extend serum half-life of interleukin-2 variants, reducing regulatory T cell activation and toxicity.

Chimeric protein-modified exosomes target cancer cells to minimize damage to normal tissues during drug delivery.

Inducible immunoevasins suppress MHC class I on CAR T cells, enabling NK cell-mediated elimination while avoiding CRISPR off-target effects.

Allogeneic T-cell precursors undergo thymic education to eliminate graft-versus-host disease risk while maintaining anti-tumor activity.

Merging PD-1 and 4-1BB domains into a single chimeric receptor reverses tumor microenvironment inhibition, sustaining T cell proliferation and cytotoxicity.

Engineered immune cells use chimeric receptors to target DLL3-expressing tumor cells.

Nucleic acid molecules encode segmented protein constructs to induce targeted immune responses against specific disease targets.

Engineered antigen binding unit targets WT1-expressing cancer cells via specific HLA-peptide recognition, reducing off-target toxicity to normal tissues.

A dual-function fusion protein combining a human GLP-1 analog with human FGF21 linked to an immunoglobulin Fc fragment.

Disrupting TRAC and beta2M genes in anti-PTK7 CAR T cells prevents normal tissue toxicity while maintaining tumor lysis.

Bispecific antibodies targeting CD122 and common gamma chain reduce vascular leak syndrome by blocking high-affinity receptor binding on endothelial cells.

CAR-Treg cells targeting glial markers suppress neuroinflammation, halting autoimmune damage in progressive supranuclear palsy and Parkinson's disease.

Anchoring interleukin-12 to the cell membrane reduces systemic toxicity while maintaining anti-tumor efficacy through localized immune activation.

Peptides target the SHP2 N-SH2 domain to inhibit protein-protein interactions, addressing poor specificity and off-target effects of existing inhibitors.

Humanized ROR1 chimeric antigen receptors reduce immunogenicity to improve T cell persistence and therapeutic efficacy.

Engineered ALCAM-binding moieties facilitate targeted immune cell delivery across the blood-brain barrier.

VHH domains enable CAR T cells to bind cryptic mesothelin epitopes, resolving antibody stability and access trade-offs.

Inducible dominant negative PD-1 balances acute T-cell activation with long-term memory persistence by dynamically regulating inhibitory signals.

A superoxide dismutase enzyme breaks down polyolefin hydrocarbon chains into biodegradable products like PHA and fatty acids.

Recombinant Staphylococcus epidermidis secretes human filaggrin to address filaggrin deficiency and restore skin barrier function in ichthyosis vulgaris.

BDCA2-CAR NK cells eliminate BPDCN tumors while minimizing cytokine release syndrome compared to traditional CAR-T therapies.

P97-trastuzumab fusion proteins transport trastuzumab across the blood-brain barrier to target HER2-positive cancer cells.